IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v44y2021i11d10.1007_s40264-021-01104-9.html
   My bibliography  Save this article

Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report

Author

Listed:
  • Toyotaka Iguchi

    (Pharmaceuticals and Medical Devices Agency)

  • Hikari Umeda

    (Pharmaceuticals and Medical Devices Agency)

  • Michie Kojima

    (Pharmaceuticals and Medical Devices Agency)

  • Yuri Kanno

    (Pharmaceuticals and Medical Devices Agency)

  • Yuta Tanaka

    (Pharmaceuticals and Medical Devices Agency)

  • Natsumi Kinoshita

    (Pharmaceuticals and Medical Devices Agency)

  • Daisaku Sato

    (Pharmaceuticals and Medical Devices Agency)

Abstract

Introduction In mid-February, the nationwide immunization plan for the prevention of coronavirus disease 2019 (COVID-19) started in Japan (at first primarily focused on health professionals) using an mRNA-based vaccine (Pfizer/BioNTech). During the phase-in period from February to March, attention was focused on post-vaccination anaphylaxis and anaphylactoid symptoms from the viewpoint of ensuring the safety of the vaccination program. Objective The aim of this report was to provide an update on the status of anaphylaxis and anaphylactoid symptoms occurring after vaccination for COVID-19, as reported under the Adverse Event Following Immunization (AEFI) reporting system in Japan. Methods The Pharmaceutical and Medical Devices Agency (PMDA) received AEFI reports from health professionals and manufacturers under the reporting system for AEFI after vaccination for COVID-19, which has been in operation since mid-February 2021. Reported AEFIs of anaphylaxis and anaphylactoid symptoms were assessed using the Brighton Collaboration Criteria to assess diagnostic certainty. Results 1-month since Japan started the vaccination program for COVID-19 in February 2021, 578,835 doses have been administered to health professionals, with the PMDA receiving 181 suspected event reports of anaphylaxis and anaphylactoid symptoms. In 171 of these 181 cases, women developed these symptoms. Among 181 cases evaluated according to the Brighton Collaboration Criteria, 47 cases (26%) were classified as level 1–3 (reporting rate: 8.1/100,000 doses). Conclusion The results appear similar to reported AEFIs in foreign studies of coronavirus vaccine administration to health professionals, although the reporting rate was higher. Further work is needed to examine the causal relationship of anaphylaxis reactions to coronavirus vaccine administration. Issues of multiple reporting and possible sex/age bias also remain to be analyzed.

Suggested Citation

  • Toyotaka Iguchi & Hikari Umeda & Michie Kojima & Yuri Kanno & Yuta Tanaka & Natsumi Kinoshita & Daisaku Sato, 2021. "Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report," Drug Safety, Springer, vol. 44(11), pages 1209-1214, November.
    • Handle: RePEc:spr:drugsa:v:44:y:2021:i:11:d:10.1007_s40264-021-01104-9
    DOI: 10.1007/s40264-021-01104-9
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-021-01104-9
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-021-01104-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:44:y:2021:i:11:d:10.1007_s40264-021-01104-9. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.